What is StemBioSys?
StemBioSys, Inc. is a privately held biomedical company based in San Antonio, Texas, specializing in the development and manufacturing of advanced cell culture technologies. Its core proprietary platforms, licensed from the University of Texas System, are designed to create clinically useful cell therapies, primarily for the research community under the CELLvo brand. The company's focus on regenerative medicine positions it within a rapidly evolving and high-potential scientific field.
How much funding has StemBioSys raised?
StemBioSys has raised a total of $13.2M across 4 funding rounds:
Unspecified
$2.4M
Series A
$8M
Private Equity
$2.7M
Debt
$150K
Unspecified (2013): $2.4M, investors not publicly disclosed
Series A (2015): $8M, investors not publicly disclosed
Private Equity (2016): $2.7M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
What's next for StemBioSys?
The recent major strategic investment suggests StemBioSys is poised for significant expansion and further development of its regenerative medicine technologies. This capital infusion will likely fuel advancements in research and development, potentially leading to broader clinical applications and market penetration. The company's strategic financing indicates a strong belief in its patented technology and its capacity to disrupt the cell therapy landscape.
See full StemBioSys company page
